Icon Plc (NASDAQ:ICLR) has received a consensus rating of “Hold” from the twelve ratings firms that are currently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $151.44.
ICLR has been the subject of several analyst reports. BidaskClub downgraded shares of Icon from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 20th. Goldman Sachs Group downgraded shares of Icon from a “conviction-buy” rating to a “buy” rating and set a $168.00 price target for the company. in a report on Friday, December 14th. Mizuho raised shares of Icon from a “neutral” rating to a “buy” rating and boosted their price target for the company from $146.00 to $150.00 in a report on Friday, January 25th. SunTrust Banks reissued a “buy” rating and set a $161.00 price target on shares of Icon in a report on Monday, February 25th. Finally, Barclays boosted their price target on shares of Icon from $130.00 to $140.00 and gave the company an “equal weight” rating in a report on Thursday, February 21st.
Icon stock traded up $2.42 during mid-day trading on Friday, reaching $134.65. The company’s stock had a trading volume of 13,720 shares, compared to its average volume of 313,399. The company has a market cap of $7.11 billion, a PE ratio of 21.45, a P/E/G ratio of 1.65 and a beta of 0.66. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.18 and a quick ratio of 2.18. Icon has a twelve month low of $110.21 and a twelve month high of $155.33.
Icon (NASDAQ:ICLR) last announced its quarterly earnings results on Wednesday, February 20th. The medical research company reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.02. Icon had a net margin of 12.43% and a return on equity of 26.01%. The company had revenue of $679.03 million during the quarter, compared to the consensus estimate of $675.04 million. During the same quarter in the previous year, the company posted $1.43 earnings per share. The company’s revenue for the quarter was up 49.2% compared to the same quarter last year. Equities research analysts anticipate that Icon will post 6.82 earnings per share for the current year.
Hedge funds have recently bought and sold shares of the stock. CWM LLC lifted its holdings in Icon by 211.8% in the fourth quarter. CWM LLC now owns 212 shares of the medical research company’s stock worth $27,000 after purchasing an additional 144 shares during the period. Truehand Inc acquired a new stake in Icon in the fourth quarter worth about $54,000. Benjamin F. Edwards & Company Inc. lifted its holdings in Icon by 36.6% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 433 shares of the medical research company’s stock worth $56,000 after purchasing an additional 116 shares during the period. Rehmann Capital Advisory Group lifted its holdings in Icon by 75.5% in the third quarter. Rehmann Capital Advisory Group now owns 416 shares of the medical research company’s stock worth $64,000 after purchasing an additional 179 shares during the period. Finally, NumerixS Investment Technologies Inc acquired a new stake in Icon in the fourth quarter worth about $64,000. 86.41% of the stock is owned by institutional investors and hedge funds.
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Recommended Story: Understanding the different types of bonds
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.